Trials / Unknown
UnknownNCT04184453
Clinical Curative Effect Evaluation Study of Treatment of Oral Deferiprone Tablets in Aceruloplasminaemia Patients
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- First Affiliated Hospital of Fujian Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Aceruloplasminemia is an autosomal recessive disorder characterized by iron deposition in the brain and visceral organs. Deferiprone was used to treat aceruloplasminemia in previous study. In this study, we will assess the clinical curative effect evaluation of oral deferiprone in Chinese aceruloplasminemia patients.
Detailed description
Diabetes is one of the most severe symptom in aceruloplasminemia. In this study, we use R2\* of pancreas MRI to evaluate the effect of deferiprone treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deferiprone treated | Deferiprone (25 mg/kg/day) was given to the enrolled patients. |
Timeline
- Start date
- 2019-12-23
- Primary completion
- 2022-10-23
- Completion
- 2022-11-23
- First posted
- 2019-12-03
- Last updated
- 2021-11-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04184453. Inclusion in this directory is not an endorsement.